Education
2001-2005 B.S., Nanyang Normal University, China
2005-2008 M.S., Capital Normal University, China
2008-2012 Ph.D., Peking University, China
Academic Experience
2012-2013 Research Associate, Institute of Microbiology, Chinese Academy of Sciences, China
2013-2015 Postdoctoral Fellow, Beth Israel Deaconess Medical Center, Harvard Medical School, USA
2015-2018 Instructor, Beth Israel Deaconess Medical Center, Harvard Medical School, USA
2019- Professor, Medical Research Institute, Wuhan University, China
2019- PI, Frontier Science Center for Immunology and Metabolism, Wuhan University, China
2019- PI, Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, China
2022- PI, Taikang Center for Life and Medical Sciences, Wuhan University, China
Awards & Honors
USA NIH/NCI K99/R00 Pathway to Independence Award (1 K99 CA212292-01) (2017)
Yongjin Distinguished Research Award from Chinese Scientists and Scholars Association of Harvard Medical School (2018)
Representative Publications
1. Zhang JF#, Bu X#, Wang HZ#, Zhu YS, Geng Y, Nihira NT, Tan YY, Ci YP, Wu F, Dai XP, Guo JP, Huang YH, Fan CQ, Ren SC, Sun YH, Freeman GJ*, Sicinski P*, Wei WY* (2018). Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553(7686):91-95.
2. Zhang JF#, Dang F#, Ren J, Wei WY* (2018). Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. Trends Biochem Sci 43(12)：1014-1032.
3. Zhang JF#, Lee YR#, Dang FB#, Gan WJ, Menon AV, Katon JM, Hsu CH, Asara JM, Tibarewal P, Leslie NR, Shi Y, Pandolfi PP*, Wei WY* (2019). PTEN Methylation by NSD2 Controls Cellular Sensitivity to DNA Damage. Cancer Discovery (9):1306-1323.
4. Zhang JF#, Chen M#, Zhu YS#, Dai XP, Dang FB, Ren JM, Ren SC, Shulga YV, Beca F, Gan WJ, Wu F, Lin YM, Zhou XB, DeCaprio JA, Beck AH, Lu KP, Huang J, Zhao C, Sun YH, Gao X*, Pandolfi PP*, Wei WY* (2019). SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression. Developmental Cell 48(3):329-344.e5.
5. Xiong WJ#, Gao Y#, Wei WY*, Zhang JF* (2021). Extracellular and nuclear PD-L1 in modulating cancer immunotherapy. Trends in Cancer 7(9):837-846.
6. Xiong WJ#, Gao XL#, Zhang TT, Jiang BS, Hu MM, Bu X, Gao Y, Zhang LZ, Xiao BL, He C, Sun YS, Li HO, Shi J, Xiao XL, Xiang BL, Xie CH, Chen G, Zhang HJ, Wei WY, Freeman GJ, Shu HB, Wang HZ*, Zhang JF* (2022). USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy. Nature Communications 13(1):1700.
7. Xiao XL#, Shi J#, He C#, Bu X, Sun YS, Gao ML, Xiang BL, Xiong WJ, Dai PP, Mao Q, Xing XX, Yao YM, Yu HS, Xu GS, Li SQ, Ren Y, Chen BX, Jiang CQ, Meng G, Lee YR, Wei WY, Freeman GJ, Xie CH*, Zhang JF* (2023). ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. Nature Communications 14(1): 2859.
8. Yu HS#, Liu J#, Bu X#, Ma ZQ#, Yao YM, Li JF, Zhang TT, Song WJ, Xiao XL, Sun YS, Xiong WJ, Shi J, Dai PP, Xiang BL, Duan HT, Yan XL, Wu F, Zhang WC, Lin DD, Hu HK, Zhang HJ, Slack FJ, He HH, Freeman GJ*, Wei WY*, Zhang JF* (2024). Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapy. Cell Chem Biol 31(4):776-791.
9. He C#, Xing XX#, Chen HY, Gao ML, Shi J, Xiang BL, Xiao XL, Sun YS, Yu HS, Xu GS, Yao YM, Xie ZS, Xing YJ, Budiarto BR, Chen SY, Gao Y, Lee YR*, Zhang JF* (2024). UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity. Molecular Cell 84(6):1120-1138.
10. Li HO#, Sun YS#, Yao YM#, Ke SW, Zhang NN, Xiong WJ, Shi J, He C, Xiao XL, Yu HS, Dai PP, Xiang BL, Xing XX, Xu GS, Song WJ, Song JQ, Zhang JF* (2024). USP8-governed GPX4 homeostasis orchestrates ferroptosis and cancer immunotherapy. PNAS 121(16): e2315541121.
